Journey Medical Corp. (DERM) intrinsic value & 10-year financials
Journey Medical Corp. (DERM) has a Graham intrinsic value of $9.16 per share. At $4.97 on Oct 17, 2026, the stock trades 46% below that value. Over the last 7 fiscal years revenue grew 6.6% a year to $61.2M, with an average return on invested capital of -343.9%.
- Graham intrinsic value
- $9.16
- Share price (Oct 17, 2026)
- $4.97
- Price vs Graham value
- 46% below
- Market cap
- $121.6M
- Revenue (FY2025)
- $61.2M
- Revenue growth (7-yr CAGR)
- 6.6%
- ROIC (10-yr avg)
- -343.9%
- Free cash flow (FY2025)
- —
DERM 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $61.2M | -$11.4M | -$0.47 | — | -13.3% | -28.3% |
| FY2024 | $55.1M | -$14.7M | -$0.72 | -$24.1M | -24.8% | -84.7% |
| FY2023 | $59.7M | -$3.9M | -$0.21 | $240.0K | -3.5% | -33.3% |
| FY2022 | $71.0M | -$29.6M | -$1.69 | -$33.5M | -38.8% | -560.1% |
| FY2021 | $63.1M | -$44.0M | -$4.32 | — | -55.2% | -1627.7% |
| FY2020 | $44.5M | $5.3M | $0.49 | — | 17.6% | 270.6% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Journey Medical Corp revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Journey Medical Corp has historically struggled to out-earn its cost of capital, averaging just -27.6% ROIC.
Journey Medical Corp capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Journey Medical Corp is modeled at 6.6% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $9.16 per share.